landogrozumab (LY2495655) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 8 Diseases   1 Trial   1 Trial   13 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
landogrozumab (LY2495655) / Eli Lilly
2011-003822-29: A Phase 2 Study in Patients with Pancreatic Cancer

Ongoing
2
120
Europe, RoW
LY2495655 for Injection, LY2495655, Lyophilisate for solution for infusion
Eli Lilly and Company
Muscle wasting and weakness associated with cancer of the pancreas that is locally advanced or metastatic, Muscle loss and weakness associated with advanced pancreas cancer, Diseases [C] - Symptoms and general pathology [C23]
 
 

Download Options